Equities research analysts expect Eli Lilly and Company (NYSE:LLY) to announce $6.58 billion in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Eli Lilly and’s earnings, with the highest sales estimate coming in at $6.68 billion and the lowest estimate coming in at $6.47 billion. Eli Lilly and reported sales of $5.50 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 19.6%. The company is scheduled to announce its next earnings report on Thursday, July 29th.
On average, analysts expect that Eli Lilly and will report full-year sales of $27.22 billion for the current fiscal year, with estimates ranging from $27.12 billion to $27.31 billion. For the next financial year, analysts expect that the company will post sales of $28.19 billion, with estimates ranging from $27.91 billion to $28.62 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Eli Lilly and.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Monday, April 26th. The company reported $1.87 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.12 by ($0.25). The firm had revenue of $6.81 billion during the quarter, compared to analysts’ expectations of $7.10 billion. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The business’s revenue for the quarter was up 16.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.75 EPS.
NYSE LLY traded up $2.28 during trading hours on Thursday, reaching $188.20. 3,676,930 shares of the company were exchanged, compared to its average volume of 4,089,341. Eli Lilly and has a 1 year low of $129.21 and a 1 year high of $218.00. The business’s 50 day simple moving average is $185.40 and its 200-day simple moving average is $176.26. The company has a quick ratio of 1.06, a current ratio of 1.36 and a debt-to-equity ratio of 3.27. The stock has a market capitalization of $180.48 billion, a P/E ratio of 30.75, a P/E/G ratio of 1.57 and a beta of 0.37.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 10th. Shareholders of record on Friday, May 14th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 1.81%. Eli Lilly and’s dividend payout ratio (DPR) is presently 56.29%.
In related news, major shareholder Lilly Endowment Inc sold 125,284 shares of Eli Lilly and stock in a transaction on Monday, March 8th. The shares were sold at an average price of $209.69, for a total value of $26,270,801.96. Following the sale, the insider now owns 110,422,933 shares in the company, valued at $23,154,584,820.77. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jackson P. Tai purchased 1,366 shares of the business’s stock in a transaction that occurred on Friday, April 30th. The stock was bought at an average price of $182.84 per share, for a total transaction of $249,759.44. Following the acquisition, the director now owns 60,649 shares of the company’s stock, valued at $11,089,063.16. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its holdings in Eli Lilly and by 51.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,094,613 shares of the company’s stock valued at $2,042,017,000 after acquiring an additional 4,082,728 shares in the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and during the 4th quarter valued at $1,463,293,000. Janus Henderson Group PLC boosted its holdings in shares of Eli Lilly and by 5.2% during the 4th quarter. Janus Henderson Group PLC now owns 6,124,921 shares of the company’s stock valued at $1,034,108,000 after buying an additional 302,296 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in shares of Eli Lilly and by 9.3% during the 1st quarter. Fisher Asset Management LLC now owns 5,508,308 shares of the company’s stock valued at $1,029,062,000 after buying an additional 470,518 shares in the last quarter. Finally, California Public Employees Retirement System boosted its holdings in shares of Eli Lilly and by 2.5% during the 4th quarter. California Public Employees Retirement System now owns 4,575,362 shares of the company’s stock valued at $772,504,000 after buying an additional 110,280 shares in the last quarter. Institutional investors and hedge funds own 75.59% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Read More: What Is an EV Stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.